Literature DB >> 2963750

Ketotifen inhibits paf-acether biosynthesis and beta-hexosaminidase release in mouse mast cells stimulated with antigen.

F Joly1, G Bessou, J Benveniste, E Ninio.   

Abstract

Acetyl-CoA acetyltransferase (1-O-alkyl-sn-glycero-3-phosphocholine) is a key enzyme in paf-acether biosynthesis. Its immunological activation as related to paf-acether formation was investigated in mast cells derived from mouse bone marrow. The action of ketotifen, a prophylactic anti-asthma drug, on the antigen-induced activation of acetyltransferase and on the release of paf-acether and beta-hexosaminidase was studied in mast cells. Mast cells were sensitized with dinitrophenyl-specific monoclonal IgE and preincubated for 15 min at 37 degrees C with various concentrations of ketotifen or vehicle prior to challenge with dinitrophenyl coupled to bovine serum albumin (40 ng/ml). Acetyltransferase activity and mediator formation and release were measured. Ketotifen inhibited dose dependently the antigen-induced paf-acether formation and release, beta-hexosaminidase release and acetyltransferase stimulation. The IC50 values were 20.0 +/- 4.4, 11.8 +/- 6.2, 8.8 +/- 3.8 and 20.5 +/- 3.4 microM (mean +/- S.E.M., n = 3) respectively. Mast cells were preincubated with 50 microM ketotifen for 15 min at 37 degrees C then washed prior to antigen challenge. The release of paf-acether and beta-hexosaminidase and the stimulation of acetyltransferase were inhibited by 90.0 +/- 15.0, 91.0 +/- 15.0 and 88.0 +/- 11.0% (n = 3) respectively. In addition, Ca2+ entry was inhibited by 100% as assessed from Quin-2 fluorescence. Thus, the release of a preformed granular enzyme beta-hexosaminidase is inhibited by ketotifen together with the enzymatic formation of a newly formed mediator.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2963750     DOI: 10.1016/0014-2999(87)90511-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Kinetic studies of human and rat neutrophil lysoPAF acetyltransferase using lysoPAF and dansyllysoPAF as substrates.

Authors:  P W Schindler; E Ninio
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

2.  Platelet-activating factor synthesis by peritoneal mast cells and its inhibition by two quinoline-based compounds.

Authors:  C M Hogaboam; D Donigi-Gale; T S Shoupe; E Y Bissonnette; A D Befus; J L Wallace
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

Review 3.  Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders.

Authors:  S M Grant; K L Goa; A Fitton; E M Sorkin
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

4.  Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis.

Authors:  J L Macpherson; A Kemp; M Rogers; A I Mallet; R F Toia; B Spur; J W Earl; C N Chesterman; S A Krilis
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

5.  Prevention of non-specific airway hyperreactivity after allergen challenge in guinea-pigs by the PAF receptor antagonist SDZ 64-412.

Authors:  A M Havill; R G Van Valen; D A Handley
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

Review 6.  Transmembrane signalling and paf-acether biosynthesis.

Authors:  E Ninio; F Joly
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

7.  Transcriptional Profiling Confirms the Therapeutic Effects of Mast Cell Stabilization in a Dengue Disease Model.

Authors:  Juliet Morrison; Abhay P S Rathore; Chinmay K Mantri; Siti A B Aman; Andrew Nishida; Ashley L St John
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

Review 8.  Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications.

Authors:  Rosa M Muñoz-Cano; Rocio Casas-Saucedo; Antonio Valero Santiago; Irina Bobolea; Paula Ribó; Joaquim Mullol
Journal:  J Clin Med       Date:  2019-08-29       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.